Treatment is generally not required for labial melanocytic macules, as they are benign
Retrieved from Hamano, S., Sawada, M., Aihara, M., et al
Coverage policies vary widely: a KFF 2025 employer survey found 43% of firms with 5,000+ workers now cover GLP-1 weight-loss drugs (up from 28% in 2024) ( [6] ), yet many patient advocacy reports and journalists note patients cutting doses or resorting to unapproved sources due to cost ( [4] ) ( [7] )
Some are research products
In 2021, an estimated 219 million people about 4.3% of the worlds adult population reported using the drug, per the United Nations Office on Drugs and Crime